首页> 外文期刊>Journal of clinical apheresis. >Indication‐specific immunomodulatory effects of extracorporeal photopheresis: A pilot study in heart transplanted patients
【24h】

Indication‐specific immunomodulatory effects of extracorporeal photopheresis: A pilot study in heart transplanted patients

机译:体外光学施术的指标特异性免疫调节作用:心脏移植患者的试验研究

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background The clinical use of extracorporeal photopheresis (ECP) is based on its ability to induce cell‐mediated immune tolerance towards foreign and self‐antigens. Up‐to‐date, no clear consensus consists on how to use ECP after heart transplantation (HTx). In this pilot study, we evaluated the stimulatory effects of ECP on immune cells in HTx patients. Methods HTx patients received ECP therapy as prophylaxis of rejection (PRX, n ?=?15), to treat acute cellular rejection (ACR, n ?=?13) or cardiac allograft vasculopathy (CAV, n ?=?5). Three ECP cycles with monthly frequency were performed. Blood samples were taken before every ECP cycle and 2 months after the last ECP cycle and were analyzed for cytokines and the tolerance‐inducing cell subsets regulatory T cells (T regs ), myeloid (mDCs), and plasmacytoid dendritic cells (pDCs). Results While ECP treatment induced first an increase of pDCs in the CAV group (baseline: 22.0%?±?9.6%, prior third ECP cycle: 8.6%?±?3.2%, follow‐up: 31.5%?±?8.4%, P ?=?.009), no significant changes of DC subsets and T regs were observed in the ACR‐ and in the PRX group. Furthermore, analysis of the immune balance showed different response profiles of pro‐ and anti‐inflammatory cytokines among prophylactically ECP‐treated patients and ECP‐treated patients suffering from CAV or ACR. Conclusions In our pilot study, we showed different stimulatory effects of ECP on pDCs and cytokines among prophylactic and therapeutic ECP therapy after HTx. Immunological monitoring should be included in a larger clinical study of ECP treatment following HTx and to identify predictable parameters for ECP efficacy.
机译:摘要背景体外光咽(ECP)的临床应用是基于其诱导细胞介导的细胞介导的免疫耐受对外来抗原的能力。最新的,没有明确的共识包括心脏移植(HTX)后如何使用ECP。在该试点研究中,我们评估了ECP对HTX患者免疫细胞的刺激作用。方法HTX患者接受ECP疗法作为抑制的预防(PRX,N?= 15),治疗急性细胞排斥(ACR,N 2 = 13)或心脏异种移植血管病变(CAV,N?=?5)。进行每月频率的三个ECP循环。在每个ECP循环和最后一次ECP循环后2个月之前采集血液样品,并分析细胞因子和诱导细胞亚群调节T细胞(T REGS),髓样(MDC)和血浆骨质特性细胞(PDC)。结果ECP治疗诱导了CAV组中PDC的增加(基线:22.0%?±9.6%,先前的第三ECP周期:8.6%?±3.2%,随访:31.5%?±8.4%, p?= 009),在ACR-和PRX组中没有观察到DC子集和T regs的显着变化。此外,免疫平衡的分析显示了预防ECP治疗的患者和患有CAV或ACR的ECP治疗的患者的抗炎细胞因子的不同反应谱。结论在我们的试验研究中,我们对HTX后预防性和治疗ECP治疗的PDC和细胞因子展示了不同的刺激作用。免疫学监测应包括在HTX之后的ECP处理的临床研究中,并鉴定ECP疗效的可预测参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号